- Home
- AVIR
as 07-26-2024 4:00pm EST
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 311.4M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 242.5K |
| Analyst Decision: | Sell | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.77 - $4.60 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Atea Pharmaceuticals Inc. (AVIR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Polsky Bruce | AVIR | Director | Jun 20 '24 | Sell | $3.49 | 17,544 | $61,144.35 | 65,606 | SEC Form 4 |
| Sommadossi Jean-Pierre | AVIR | President, CEO, and Chairman | Jun 5 '24 | Sell | $4.00 | 1,006 | $4,024.00 | 5,923,994 | SEC Form 4 |
| Sommadossi Jean-Pierre | AVIR | President, CEO, and Chairman | Jan 31 '24 | Sell | $3.85 | 56,910 | $218,818.95 | 116,557 | SEC Form 4 |
| Vavricka John | AVIR | Chief Commercial Officer | Jan 31 '24 | Sell | $3.84 | 11,819 | $45,420.42 | 21,515 | SEC Form 4 |
| Horga Maria Arantxa | AVIR | Chief Medical Officer | Jan 31 '24 | Sell | $3.84 | 15,870 | $60,963.02 | 25,664 | SEC Form 4 |
| Foster Wayne | AVIR | EVP, Chief Accounting Officer | Jan 31 '24 | Sell | $3.84 | 12,477 | $47,904.19 | 20,857 | SEC Form 4 |
| Corcoran Andrea | AVIR | See Remarks | Jan 31 '24 | Sell | $3.84 | 15,843 | $60,914.75 | 670,208 | SEC Form 4 |
| Hammond Janet MJ | AVIR | Chief Development Officer | Jan 31 '24 | Sell | $3.84 | 14,029 | $53,913.45 | 35,362 | SEC Form 4 |
Latest Atea Pharmaceuticals Inc. News
AVIR Breaking Stock News: Dive into AVIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
GlobeNewswire
2 months ago
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
GlobeNewswire
2 months ago
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
GuruFocus.com
2 months ago
Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
GlobeNewswire
2 months ago
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
3 months ago
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
GlobeNewswire
3 months ago
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
GlobeNewswire
4 months ago
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Compare AVIR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVIR Atea Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.